Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Leuk Res 2018 09 10;72:92-95. Epub 2018 Aug 10.

The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183018
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.08.005DOI Listing
September 2018
13 Reads

Publication Analysis

Top Keywords

versus cytarabine
4
mitoxantrone versus
4
cytarabine mitoxantrone
4
acute myeloid
4
high-risk acute
4
cytarabine daunorubicin
4
7 + 3 newly
4
diagnosed high-risk
4
daunorubicin 7 + 3
4
newly diagnosed
4
alvocidib cytarabine
4
randomized multicenter
4
leukemia aml
4
final randomized
4
myeloid leukemia
4
multicenter phase
4
phase study
4
study alvocidib
4
cytarabine
2
high-risk
1

Similar Publications